- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
- Interventions
- TriVerity
- Diagnostic Test
- Lead sponsor
- Inflammatix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Los Angeles, California • Sacramento, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 1,733
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma, IDH-Wildtype
- Interventions
- Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
- Conditions
- High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Lavage, Pap Smear
- Other · Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Iberdomide, Magnetic Resonance Imaging, Patient Monitoring, Positron Emission Tomography, Skeletal Survey X-Ray
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 74
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 55 more
- Conditions
- Metabolism, Inborn Errors, Hearing Loss, Hereditary Disease
- Interventions
- Well infant, whole exome sequencing, Diagnosed, whole exome sequencing
- Genetic
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 1 Hour to 5 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Biliary Tract Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Brain Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pancreatobiliary Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Pancreatic Cancer, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Pancreatic Cancer, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Acute Kidney Injury
- Interventions
- Urine collection for NEPHROCLEAR CCL14 Test
- Diagnostic Test
- Lead sponsor
- Astute Medical, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- biologic sample preservation procedure, immunohistochemistry staining method, light microscopy, medical chart review, histopathologic examination, needle biopsy, spectroscopy
- Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry, Electronic Health Record Review, Exercise Intervention, Physical Examination, Questionnaire Administration, Spirometry, Physical Performance Testing, Best Practice
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7,776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2009
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana + 4 more
- Conditions
- Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
- Interventions
- Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
- Procedure · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage I Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor, Stage IV Wilms Tumor, Stage V Wilms Tumor
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- Arcadia, California • West Palm Beach, Florida
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
- Interventions
- Risk reduction, Medical records-based recommendation, Algorithm-based recommendation
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 117,649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer, Gastrointestinal Stromal Tumor, HER2-negative Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Cell Lung Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Triple-negative Breast Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma, Unresectable Melanoma
- Interventions
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
- Drug · Biological · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 75 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 176
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
- Conditions
- Solid Tumors, Hematological Malignancies
- Interventions
- Molecular Analysis of Cancer
- Other
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- East Greenwich, Rhode Island • Providence, Rhode Island
- Conditions
- Prostate Cancer
- Interventions
- MRI with DBSI analysis
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
- Interventions
- Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept, X-Ray Imaging
- Procedure · Biological
- Lead sponsor
- Seth Pollack
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 198
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 157 more
- Conditions
- Postpartum Depression (PPD), Pregnancy
- Interventions
- Diagnostic Test: Enlighten
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia